RU2009134039A - Стимуляторы tgf-бета и другие агенты для уменьшения побочных эффектов - Google Patents
Стимуляторы tgf-бета и другие агенты для уменьшения побочных эффектов Download PDFInfo
- Publication number
- RU2009134039A RU2009134039A RU2009134039/15A RU2009134039A RU2009134039A RU 2009134039 A RU2009134039 A RU 2009134039A RU 2009134039/15 A RU2009134039/15 A RU 2009134039/15A RU 2009134039 A RU2009134039 A RU 2009134039A RU 2009134039 A RU2009134039 A RU 2009134039A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredients
- disease
- tamoxifen
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title claims abstract 5
- 230000000694 effects Effects 0.000 title claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000000021 stimulant Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 19
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 229960001603 tamoxifen Drugs 0.000 claims abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 6
- 239000004615 ingredient Substances 0.000 claims abstract 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims abstract 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims abstract 2
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims abstract 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims abstract 2
- 229950004203 droloxifene Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 239000008240 homogeneous mixture Substances 0.000 claims abstract 2
- 229950002248 idoxifene Drugs 0.000 claims abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract 2
- 229960005026 toremifene Drugs 0.000 claims abstract 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 4
- 229960003009 clopidogrel Drugs 0.000 claims 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- 229940127218 antiplatelet drug Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010051787 Multiple organ transplant rejection Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- CMDYHTIDHSNRGW-UHFFFAOYSA-L copper;2-acetyloxybenzoate Chemical compound [Cu+2].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O CMDYHTIDHSNRGW-UHFFFAOYSA-L 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 229960002240 iloprost Drugs 0.000 claims 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003425 tirofiban Drugs 0.000 claims 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0702871.5 | 2007-02-14 | ||
| GBGB0702871.5A GB0702871D0 (en) | 2007-02-14 | 2007-02-14 | Improved compositions and combinations 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009134039A true RU2009134039A (ru) | 2011-03-20 |
Family
ID=37908631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009134039/15A RU2009134039A (ru) | 2007-02-14 | 2008-02-07 | Стимуляторы tgf-бета и другие агенты для уменьшения побочных эффектов |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100099642A1 (https=) |
| EP (1) | EP2121020A2 (https=) |
| JP (1) | JP2010518154A (https=) |
| CN (1) | CN101668543A (https=) |
| CA (1) | CA2678127A1 (https=) |
| GB (1) | GB0702871D0 (https=) |
| RU (1) | RU2009134039A (https=) |
| WO (1) | WO2008099144A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
| US20110136858A1 (en) * | 2009-12-04 | 2011-06-09 | Grainger David J | Preferred Combination Therapy |
| GB2475907A (en) | 2009-12-04 | 2011-06-08 | Tcp Innovations Ltd | Composition comprising a mixture of clopidogrel and droloxifene |
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| CN104211778A (zh) * | 2014-09-28 | 2014-12-17 | 苏州普罗达生物科技有限公司 | 一种转化生长因子β1激动剂多肽及其制备方法、应用 |
| CN104311631A (zh) * | 2014-09-28 | 2015-01-28 | 苏州普罗达生物科技有限公司 | 转化生长因子β1激动剂多肽及其制备方法、应用 |
| US20220125744A1 (en) * | 2018-11-07 | 2022-04-28 | Health Research, Inc. | Exploiting estrogen receptor beta and tp53 interaction as a new therapeutic strategy for cancer |
| CN116152157B (zh) * | 2022-11-28 | 2026-02-27 | 苏州大学 | 基于肿瘤组织灌注影像学特征的生物标志物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251920B1 (en) * | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
-
2007
- 2007-02-14 GB GBGB0702871.5A patent/GB0702871D0/en not_active Ceased
-
2008
- 2008-02-07 US US12/527,337 patent/US20100099642A1/en not_active Abandoned
- 2008-02-07 RU RU2009134039/15A patent/RU2009134039A/ru not_active Application Discontinuation
- 2008-02-07 EP EP08709352A patent/EP2121020A2/en not_active Withdrawn
- 2008-02-07 CN CN200880009702A patent/CN101668543A/zh active Pending
- 2008-02-07 JP JP2009549466A patent/JP2010518154A/ja active Pending
- 2008-02-07 CA CA002678127A patent/CA2678127A1/en not_active Abandoned
- 2008-02-07 WO PCT/GB2008/000451 patent/WO2008099144A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2678127A1 (en) | 2008-08-21 |
| WO2008099144A3 (en) | 2008-12-04 |
| GB0702871D0 (en) | 2007-03-28 |
| JP2010518154A (ja) | 2010-05-27 |
| US20100099642A1 (en) | 2010-04-22 |
| CN101668543A (zh) | 2010-03-10 |
| EP2121020A2 (en) | 2009-11-25 |
| WO2008099144A2 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009134039A (ru) | Стимуляторы tgf-бета и другие агенты для уменьшения побочных эффектов | |
| RU2005104418A (ru) | Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2010518154A5 (https=) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JPS62181216A (ja) | 神経変性症の予防及び治療における特異的ｎ―メチル―ｄ―アスパラギン酸エステルレセプター拮抗剤としての用途 | |
| JP2012525393A5 (https=) | ||
| KR20170131650A (ko) | 글루타미나제 억제제의 투여 방법 | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| PL193405B1 (pl) | Zastosowanie wybiórczych inhibitorów pośrednich czynnika Xa w połączeniu z substancją hamującą agregację płytek krwi do wytwarzania leku do leczenia zakrzepowo-zatorowych chorób tętnic oraz preparatyfarmaceutyczne | |
| RU2012135698A (ru) | Способ и композиция | |
| RU2010142847A (ru) | Противовоспалительные агенты | |
| RU2022104034A (ru) | Фармацевтические композиции | |
| CN1812792A (zh) | 双嘧达莫或单哌潘生丁用于治疗和预防凝血酶过量产生和/或凝血酶受体表达增加引起的血栓栓塞疾病和紊乱 | |
| TW202143967A (zh) | 包含jak3/jak1/tbk1抑制劑和甲氨蝶呤的藥物組合物及其用途 | |
| CN1382145A (zh) | 神经性疼痛治疗剂和神经性疼痛的动物模型 | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| BR112020025670A2 (pt) | Alcóxi pirazóis como ativadores de guanilato ciclase solúveis | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| RU2017137008A (ru) | Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени | |
| JP2008509210A5 (https=) | ||
| JP2020502106A5 (https=) | ||
| JP7735862B2 (ja) | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 | |
| WO2006104086A1 (ja) | 血栓症治療剤 | |
| JP2022528481A (ja) | ピモジドとメトトレキサートの医薬組成物、及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130826 |